Hemopoietic stem cell transplantation for myelodysplastic syndrome

Current Opinion in Oncology

Volumn 12, Issue 2, 2000, Pages 116-120

  Deeg, H Joachim ^a   Appelbaum, Frederick R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; MORTALITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034501288     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200003000-00003     Document Type: Review

References (31)

1. Proposals for the classification of the myelodysplastic syndromes
2. International scoring system for evaluating prognosis in myelodysplastic syndromes
3. Stem cell transplantation in myelodysplastic syndromes
4. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors
5. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia
6. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
7. Allogeneic marrow transplantation for myelodysplastic syndrome (MDS)
8. Unrelated donor (URD) bone marrow transplantation (BMT) for refractory anemia (RA)
9. The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS)
10. Stem cell transplantation and intensified cytotoxic treatment for myelodysplasia
11. Delayed platelet regeneration following allogeneic peripheral blood progenitor cell transplantation for acute leukemia
12. Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
13. Phase II study of busulfan (BU) and total body irradiation (TBI) as a novel preparative regimen in allogenic marrow transplantation (BMT) for advanced myelodysplastic syndrome
14. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
15. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation
16. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55-66 years of age
17. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation
18. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-hodgkin's lymphoma
19. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey
20. Myelodysplastic syndrome occurring after autologous bone marrow transplantation for lymphoma. Morphologic features
21. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia
22. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7
23. Morphologic, immunologic, and cytogenetic Classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: A report from the Childrens Cancer Group
24. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: A report from the European Working Group on Myelodysplastic Syndrome in Childhood
25. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t
26. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia
27. Bone marrow transplantation for children less than 2 years of age with acute myetogenous leukemia or myelodysplastic syndrome
28. Emerging role of topoisomerase I inhibitors in the therapy of high risk MDS and CMML
29. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes
30. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
31. Phase I study of 1311-Anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome